Further research on changes of other biomarkers, such as cystatin c and NGAL,other pathological and functional aspects of the kidney, and also details of apoptoticpathways are necessary to confidently consider the clinical application of hEnSCs for thetreatment of renal diseases. The gene discussed is CST3; the disease is kidney disorder.